Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies BioTime, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: BioTime is a biotechnology company focused on two areas: (1) blood plasma volume expanders, primarily Hextend®, distributed by Hospira and CJ CheilJedang; and (2) regenerative medicine research products (stem cells) marketed through its subsidiary, Embryome Sciences, Inc. The company has not yet generated significant revenue from its stem cell segment.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenues | $432,090 | $728,833 |
| Net Loss | $(1,471,370) | $(2,989,584) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.11) |
| Cash and Cash Equivalents | $4,692,726 (as of June 30, 2009) | |
| Lines of Credit Payable (Net) | ||
| Total Current Liabilities | $4,249,609 | |
| Shareholders' Deficit | $(827,805) |
Revenue Breakdown (Six Months): Royalties from product sales ($574,391), License fees ($146,452), Grant income ($6,800), Other revenue ($1,190).
Expense Breakdown (Six Months): Research and development ($1,165,418), General and administrative ($1,582,320), Interest expense ($973,566).
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased from $12,279 at December 31, 2008, to $4,692,726 at June 30, 2009. This was driven by $4,000,000 in proceeds from the issuance of common shares and $2,310,000 in new borrowings under the line of credit.
- Revenue Decline (YTD): Total revenues for the six months ended June 30, 2009 ($728,833) decreased by approximately 8% compared to the same period in 2008 ($791,581), primarily due to a decrease in royalty revenues from product sales.
- Increased Expenses: Net loss widened significantly. Operating expenses increased by 59% year-over-year for the six-month period, driven by higher R&D costs (up 53%) and General & Administrative costs (up 63%). G&A increases were largely due to stock appreciation rights compensation liability.
- Debt Position: Lines of credit payable increased from $1,885,699 to $3,314,033. The company has essentially fully subscribed its $3.5 million revolving credit facility.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Financing: The company raised $8,000,000 in equity capital in May and July 2009 (the July portion is a subsequent event). Management expects to rely on royalties from Hextend and future equity financing to fund operations.
- Grant Funding: In April 2009, the California Institute of Regenerative Medicine (CIRM) awarded a $4.7 million grant for stem cell research, with approximately $1.6 million expected in the first 12 months.
- Product Pipeline: Embryome Sciences is launching new stem cell research products and growth media in partnership with Millipore Corporation. No therapeutic products are currently generating revenue.
Risks and Contingencies:
- Liquidity Risk: The company has a history of net losses and an accumulated deficit of over $50 million. Continued operations depend on successful commercialization of Hextend, licensing of stem cell products, and the ability to secure additional financing.
- Debt Maturity: The revolving line of credit matures on December 1, 2009. The company is conducting an exchange offer to convert debt to equity to manage this maturity.
- Regulatory & Commercial: Success depends on FDA approvals for therapeutic products and the ability of licensees (Hospira, CJ, Summit) to maintain sales and regulatory compliance. Summit's sublicensee in Japan (Maruishi) withdrew, creating uncertainty for that market.
Investor Verification Checklist
- Debt Conversion Status: Verify the outcome of the Exchange Offer for the Revolving Credit Notes maturing December 1, 2009, and the extent of dilution from converting debt to equity.
- Grant Disbursement: Confirm the timing and actual receipt of the $4.7 million CIRM grant funds, as this is critical for funding R&D.
- Equity Dilution: Review the impact of the $8 million equity raise (May/July 2009) and the issuance of shares for services/debt on existing shareholder ownership.
- Hextend Sales Trends: Monitor royalty reports from Hospira and CJ to assess if the decline in Q2 2009 royalties is a temporary fluctuation or a structural decline.
- Summit Pharmaceuticals: Track the progress of Summit in finding a replacement sublicensee for the Japanese market following Maruishi's withdrawal.